The nigrostriatal DA pathway and Parkinson's disease

Journal of Neural Transmission, Supplement

Volumn , Issue 70, 2006, Pages 71-83

  Fuxe, K ^a   Manger, P ^b   Genedani, S ^c   Agnati, L ^c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE A2A RECEPTOR ANTAGONIST; ADENOSINE RECEPTOR BLOCKING AGENT; AMPHETAMINE; ANTIPARKINSON AGENT; DOPAMINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; LEVODOPA; METHYLXANTHINE DERIVATIVE; N METHYL DEXTRO ASPARTIC ACID; NEUROPROTECTIVE AGENT; OPIATE RECEPTOR; SEROTONIN; SEROTONIN AGONIST;

CENTRAL NERVOUS SYSTEM; CONFERENCE PAPER; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; FLUORESCENCE; HISTOCHEMISTRY; LABORATORY TEST; NEOSTRIATUM; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION;

EID: 33750289921     PISSN: 03036995     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-211-45295-0_13     Document Type: Conference Paper

References (82)

1. Agnati LF, Cortelli P, Pettersson R, Fuxe K (1995) The concept of trophic units in the central nervous system. Prog Neurobiol 46: 561-574
2. Agnati LF, Ferre S, Lluis C, Franco R, Fuxe K (2003b) Molecular mechanisms and therapeutical implications of intramembrane receptor/receptor interactions among heptahelical receptors with examples from the striatopallidal GABA neurons. Pharmacol Rev 55: 509-550
3. Agnati LF, Fuxe K, Andersson K, Benfenati F, Cortelli P, D'Alessandro R (1980a) The mesolimbic dopamine system: evidence for a high amine turnover and for a heterogeneity of the dopamine neuron population. Neurosci Lett 18: 45-51
4. Agnati LF, Fuxe K, Zini I, Lenzi P, Hokfelt T (1980b) Aspects on receptor regulation and isoreceptor identification. Med Biol 58: 182-187
5. Agnati LF, Fuxe K, Ferre S (2005a) How receptor mosaics decode transmitter signals. Possible relevance of cooperativity. Trends Biochem Sci 30: 188-193
6. Agnati LF, Fuxe K, Zoli M, Rondanini C, Ogren SO (1982) New vistas on synaptic plasticity: the receptor mosaic hypothesis of the engram. Med Biol 60: 183-190
7. Agnati LF, Fuxe K, Zoli M, Ozini I, Toffano G, Ferraguti F (1986) A correlation analysis of the regional distribution of central enkephalin and beta-endorphin immunoreactive terminals and of opiate receptors in adult and old male rats. Evidence for the existence of two main types of communication in the central nervous system: the volume transmission and the wiring transmission. Acta Physiol Scand 128: 201-207
8. Agnati LF, Fuxe K, Zoli M, Ferraguti F, Benfenati F, Ouimet CC, Walaas SI, Hemmings HC Jr, Goldstein M, Greengard P (1988) Morphometrical evidence for a complex organization of tyrosine hydroxylase-, enkephalin- and DARPP-32-like immunoreactive patches and their codistribution at three rostrocaudal levels in the rat neostriatum. Neuroscience 27: 785-797
9. Agnati LF, Fuxe K, Benfenati F, Zini I, Zoli M, Fabbri L, Harfstrand A (1984) Computer-assisted morphometry and microdensitometry of transmitter-identified neurons with special reference to the mesostriatal dopamine pathway. Methodological aspects. Acta Physiol Scand [Suppl] 532: 5-36
10. Agnati LF, Franzen O, Ferre S, Leo G, Franco R, Fuxe K (2003a) Possible role of intramembrane receptor-receptor interactions in memory and learning via formation of long-lived heteromeric complexes: focus on motor learning in the basal ganglia. J Neural Transm [Suppl]: 1-28
11. Agnati LF, Genedani S, Lenzi PL, Leo G, Mora F, Ferre S, Fuxe K (2005b) Energy gradients for the homeostatic control of brain ECF composition and for VT signal migration: introduction of the tide hypothesis. J Neural Transm 112: 45-63
12. Anden NE, Carlsson A, Dahlstroem A, Fuxe K, Hillarp NA, Larsson K (1964) Demonstration and mapping out of nigro-neostriatal dopamine neurons. Life Sci 15: 523-530
13. Anden NE, Dahlstroem A, Fuxe K, Larsson K (1965) Further evidence for the presence of nigro-neostriatal dopamine neurons in the rat. Am J Anat 116: 329-333
14. Antonelli T, Ferraro L, Agnati L, Tanganelli S, Fuxe K (2006) Experimental studies and theoretical aspects on A2A/D2 receptor interactions in a model of Parkinson's disease. Relevance for 1-dopa induced dyskinesias. J Neurol Sci (in press)
15. 2 underlies glutamate-dependent inhibition of striatal dopamine release. Proc Natl Acad Sci USA 100: 11729-11734
16. Baraldi PG, Di Virgilio F, Romagnoli R (2004) Agonists and antagonists acting at P2X7 receptor. Curr Top Med Chem 4: 1707-1717
17. Barja G (2004) Free radicals and aging. Trends Neu-rosci 27: 595-600
18. Battista A, Fuxe K, Goldstein M, Ogawa M (1972) Mapping of central monoamine neurons in the monkey. Experientia 28: 688-690
19. Beal MF (2000) Energetics in the pathogenesis of neurodegenerative diseases. Trends Neurosci 23: 298-304
20. Bjorklund A, Lindvall O (1975) Dopamine in dendrites of substantia nigra neurons: suggestions for a role in dendritic terminals. Brain Res 83: 531-537
21. Bordet R, Ridray S, Schwartz JC, Sokoloff P (2000) Involvement of the direct striatonigral pathway in levodopa-induced sensitization in 6-hydroxydopamine-lesioned rats. Eur J Neurosci 12: 2117-2123
22. Braak H, Ghebremedhin E, Rub U, Bratzke H, Del Tredici K (2004) Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 318: 121-134
23. Braak H, Rub U, Gai WP, Del Tredici K (2003) Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J Neural Transm 110: 517-536
24. + channels. Diabetes 53 [Suppl 3]: S104-S112
25. Burnstock G, Knight GE (2004) Cellular distribution and functions of P2 receptor subtypes in different systems. Int Rev Cytol 240: 31-304
26. Busija DW, Lacza Z, Rajapakse N, Shimizu K, Kis B, Bari F, Domoki F, Horiguchi T (2004) Targeting mitochondrial ATP-sensitive potassium channels - a novel approach to neuroprotection. Brain Res Brain Res Rev 46: 282-294
27. Canals M, Marcellino D, Fanelli F, Ciruela F, de Benedetti P, Goldberg SR, Neve K, Fuxe K, Agnati LF, Woods AS, Ferre S, Lluis C, Bouvier M, Franco R (2003) Adenosine A2A-dopamine D2 receptor-receptor heteromerization: qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer. J Biol Chem 278: 46741-46749
28. Carlsson A, Falck B, Hillarp NA (1962) Cellular localization of brain monoamines. Acta Physiol Scand 56 [Suppl 196]: 1-28
29. Chase TN (2004) Striatal plasticity and extrapyramidal motor dysfunction. Parkinsonism Relat Disord 10: 305-313
30. Ciruela F, Burgueno J, Casado V, Canals M, Marcellino D, Goldberg SR, Bader M, Fuxe K, Agnati LF, Lluis C, Franco R, Ferre S, Woods AS (2004) Combining mass spectrometry and pull-down techniques for the study of receptor heteromerization. Direct epitope-epitope electrostatic interactions between adenosine A2A and dopamine D2 receptors. Anal Chem 76: 5354-5363
31. Dahlstroem A, Fuxe K (1964a) Evidence for the existence of monoamine-containing neurons in the central nervous system. I. Demonstration of monoamines in the cell bodies of brain stem neurons. Acta Physiol Scand 62 [Suppl 232]: 231-255
32. Dahlstroem A, Fuxe K (1964b) A method for the demonstration of monoamine-containing nerve fibres in the central nervous system. Acta Physiol Scand 60: 293-294
33. Da Silva J, Fuxe K, Manger P (2006) Nuclear parcellation of certain immunohistochemically identifiable neuronal systems in the midbrain and pons of the highveld molerat (Cryptomys hottentotus). J Chem Neuroanat 31: 37-50
34. Dauer W, Przedborski S (2003) Parkinson's disease: mechanisms and models. Neuron 39: 889-909
35. de la Fuente-Fernandez R, Calne DB (2002) Evidence for environmental causation of Parkinson's disease. Parkinsonism Relat Disord 8: 235-241
36. Descarries L, Beaudet A, Watkins KC (1975) Serotonin nerve terminals in adult rat neocortex. Brain Res 100: 563-588
37. Ferre S, von Euler G, Johansson B, Fredholm BB, Fuxe K (1991) Stimulation of high-affinity adenosine A2 receptors decreases the affinity of dopamine D2 receptors in rat striatal membranes. Proc Natl Acad Sci USA 88: 7238-7241
38. Fields RD, Stevens B (2000) ATP: an extracellular signaling molecule between neurons and glia. Trends Neurosci 23: 625-633
39. Fuxe K (1965a) Evidence for the existence of monoamine neurons in the central nervous system. 3. The monoamine nerve terminal. Z Zellforsch Mikrosk Anat 65: 573-596
40. Fuxe K (1965b) Evidence for the existence of monoamine neurons in the central nervous system, iv. Distribution of monoamine nerve terminals in the central nervous system. Acta Physiol Scand 64 [Suppl 247]: 39-85
41. Fuxe K (1979) DA receptor agonists in brain research and as therpautic agents. TINS 2: 1-4
42. Fuxe K, Agnati LF, Benfenati F, Cimmino M, Algeri S, Hokfelt T, Mutt V (1981) Modulation by cholecystokinins of 3H-spiroperidol binding in rat striatum: evidence for increased affinity and reduction in the number of binding sites. Acta Physiol Scand 113: 567-556
43. Fuxe K, Agnati L, Bjelke B, Hedlund P, Ueki A, Tinner B, Bunneman, Steinbusch H, Ganten D, Cintra A (1993) Novel aspects on central 5-hydroxytryptamine transmission. Focus on the cerebellum. In: Trouillas P, Fuxe K (eds) Serotonin, the cerebellum and ataxia. Raven Press, New York, pp 1-37
44. Fuxe K, Agnati LF, Jacobsen K, Million J, Canals M, Torvinen M, Tinner-Staines B, Staines W, Rosin D, Terasmaa A, Popoli P, Leo G, Vergoni V, Lluis C, Ciruela F, Franco R, Ferre S (2003a) Receptor heteromerization in adenosine A2A receptor signaling: relevance for striatal function and Parkinson's disease. Neurology 61: S19-S23
45. Fuxe K, Agnati L, Kalia M, Goldstein M, Andersson K, Härfstrand A (1985) Dopaminergic systems in the brain and pituitary. In: Fluckiger E, Muller EE, Thorner MO (eds) The dopaminergic system. Springer, Berlin Heidelberg, pp 11-25 (Basic and Clinical Aspects of Neuroscience)
46. Fuxe K, Ferre S, Franco R, Agnati L (2006) Adenosine receptor-dopamine receptor interactions in the basal ganglia and their relevance for brain function. Physiol Behav (in press)
47. Fuxe K, Ferre S, Zoli M, Agnati LF (1998) Integrated events in central dopamine transmission as analyzed at multiple levels. Evidence for intramembrane adenosine A2A/dopamine D2 and adenosine A1/dopamine D1 receptor interactions in the basal ganglia. Brain Res Brain Res Rev 26: 258-273
48. Fuxe K, Ferre S, Woods A, Rivera A, Höistad M, Franco R, Kehr J, Agnati L (2003b) Novel strategies for the treatment of Parkinson's disease. Focus on receptor-receptor interactions in the basal ganglia. In: Kehr J, Fuxe K, Ungerstedt U, Svensson T (eds) Monitoring molecules in neuroscience. Karolinska Institutet, Stockholm, pp 199-202
49. Fuxe K, Hökfelt T, Ungerstedt U (1971) Localization of monoamines in the central nervous system. In: Ajuriaguerra J, Gauthier G (eds) Monoamines noyeaux gris centraux et syndrome de Parkinson. Georg & Cie S. A., Geneve, pp 23-60
50. Fuxe K, Stromberg I, Popoli P, Rimondini-Giorgini R, Torvinen M, Ogren SO, Franco R, Agnati LF, Ferre S (2001) Adenosine receptors and Parkinson's disease. Relevance of antagonistic adenosine and dopamine receptor interactions in the striatum. Adv Neurol 86: 345-353
51. Fuxe K, Tinner B, Zoli M, Pettersson RF, Baird A, Biagini G, Chadi G, Agnati LF (1996) Computer-assisted mapping of basic fibroblast growth factor immunoreactive nerve cell populations in the rat brain. J Chem Neuroanat 11: 13-35
52. Fuxe K, Ungerstedt U (1970) Histochemical, biochemical and functional studies on central monoamine neurons after acute and chronic amphetamine administration. In: Costa E, Garattini S (eds) Amphetamines and related compounds. Raven Press, New York, pp 257-288
53. Fuxe K, Ungerstedt U (1974) Action of caffeine and theophyllamine on supersensitive dopamine receptors: considerable enhancement of receptor response to treatment with DOPA and dopamine receptor agonists. Med Biol 52: 48-54
54. rd edn. Elsevier, Amsterdam, pp 455-508
55. Gines S, Hillion J, Torvinen M, Le Crom S, Casado V, Canela EI, Rondin S, Lew JY, Watson S, Zoli M, Agnati LF, Verniera P, Lluis C, Ferre S, Fuxe K, Franco R (2000) Dopamine D1 and adenosine A1 receptors form functionally interacting heteromeric complexes. Proc Natl Acad Sci USA 97: 8606-8611
56. Grondin R, Zhang Z, Yi A, Cass WA, Maswood N, Andersen AH, Elsberry DD, Klein MC, Gerhardt GA, Gash DM (2002) Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys. Brain 125: 2191-2201
57. Hillion J, Canals M, Torvinen M, Casado V, Scott R, Terasmaa A, Hansson A, Watson S, Olah ME, Mallol J, Canela EI, Zoli M, Agnati LF, Ibanez CF, Lluis C, Franco R, Ferre S, Fuxe K (2002) Coaggregation, cointernalization, and codesensitization of adenosine A2A receptors and dopamine D2 receptors. J Biol Chem 277: 18091-18097
58. Hoistad M, Kehr J, Andbjer B, Jansson A, Fuxe K (2000) Intracerebral infusion of H-dopamine and H-mannitol in the striatum of halothane-anaesthetized male rats. A dual-probe microdialysis study of long-distance diffusion. Eur J Neurosci 12: 2505-2514
59. Horvath TL, Warden CH, Hajos M, Lombardi A, Goglia F, Diano S (1999) Brain uncoupling protein 2: uncoupled neuronal mitochondria predict thermal synapses in homeostatic centers. J Neurosci 19: 10417-10427
60. Iadecola C (1998) Neurogenic control of the cerebral microcirculation: is dopamine minding the store? Nat Neurosci 1: 263-265
61. Jacobowitz DM, Kallarakal AT (2004) Flotillin-1 in the substantia nigra of the Parkinson brain and a predominant localization in catecholaminergic nerves in the rat brain. Neurotox Res 6: 245-257
62. Janson AM, Fuxe K, Goldstein M, Deuten AY (1991) Hypertrophy of dopamine neurons in the primate following ventromedial mesencephalic tegmentum lesion. Exp Brain Res 87: 232-238
63. Jansson A, Descarries L, Cornea-Hebert V, Riad M, Verge D, Bancila, M, Agnati L, Fuxe K (2002) Transmitter-receptor mismatches in central dopamine, serotonin, and neuropeptide systems. Further evidence for volume transmission. In: Walz W (ed) The neuronal environment: brain homeostasis in health and disease. Humana Press Inc, Totowa, NJ
64. Jansson A, Goldstein M, Tinner B, Zoli M, Meador-Woodruff JH, Lew JY, Levey AI, Watson S, Agnati LF, Fuxe K (1999) On the distribution patterns of D1, D2, tyrosine hydroxylase and dopamine transporter immunoreactivities in the ventral striatum of the rat. Neuroscience 89: 473-489
65. Kamiya T, Saitoh O, Yoshioka K, Nakata H (2003) Oligomerization of adenosine A2A and dopamine D2 receptors in living cells. Biochem Biophys Res Commun 306: 544-549
66. Kanda T, Jackson MJ, Smith LA, Pearce RK, Nakamura J, Kase H, Kuwana Y, Jenner P (1998) Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Ann Neurol 43: 507-513
67. Lee FJ, Xue S, Pei L, Vukusic B, Chery N, Wang Y, Wang YT, Niznik HB, Yu XM, Liu F (2002) Dual regulation of NMDA receptor functions by direct protein-protein interactions with the dopamine D1 receptor. Cell 111: 219-230
68. Liss B, Roeper J (2001) ATP-sensitive potassium channels in dopaminergic neurons: transducers of mitochondrial dysfunction. News Physiol Sci 16: 214-217
69. Manger P (2005) Establishing order at the systems level in mammalian brain evolution. Brain Res Bull 66: 282-289
70. Manger PR, Fuxe K, Ridgway SH, Siegel JM (2004) The distribution and morphological characteristics of catecholaminergic cells in the diencephalon and midbrain of the bottlenose dolphin (Tursiops truncatus). Brain Behav Evol 64: 42-60
71. Malmfors T (1965) Studies on adrenergic nerves. The use of rat and mouse iris for direct observations on their physiology and pharmacology at cellular and subcellular levels. Acta Physiol Scand 64 [Suppl 248]: 241-293
72. Marshall FH (2001) Heterodimerization of G-protein-coupled receptors in the CNS. Curr Opin Pharmacol 1: 40-44
73. North RA (2002) Molecular physiology of P2X receptors. Physiol Rev 82: 1013-1067
74. Olson L, Seiger A, Fuxe K (1972) Heterogeneity of striatal and limbic dopamine innervation: highly fluorescent islands in developing and adult rats. Brain Res 44: 283-288
75. Rivera A, Agnati L, Horvath TL, de la Calle A, Fuxe K (2006) Uncoupling 2/3 immunoreactivity and the ascending dopaminergic and noradrenergic neuron systems. Relevance for volume transmission. Neuroscience 137: 1447-1461
76. Rivera A, Cuellar B, Giron FJ, Grandy DK, de la Calle A, Moratalla R (2002) Dopamine D4 receptors are heterogeneously distributed in the striosomes/matrix compartments of the striatum. J Neurochem 80: 219-229
77. Ruan T, Lin YS, Lin KS, Kou YR (2005) Sensory transduction of pulmonary reactive oxygen species by capsaicin-sensitive vagal lung afferent fibres in rats. J Physiol 565: 563-578
78. Tennyson VM, Barrett RE, Cohen G, Cote L, Heikkila R, Mytilineou C (1972) The developing neostriatum of the rabbit: correlation of fluorescence histochemistry, electron microscopy, endogenous dopamine levels, and (3H) dopamine uptake. Brain Res 46: 251-285
79. Torvinen M, Marcellino D, Canals M, Agnati LF, Lluis C, Franco R, Fuxe K (2005) Adenosine A2A receptor and dopamine D3 receptor interactions: evidence of functional A2A/D3 heteromeric complexes. Mol Pharmacol 67: 400-407
80. Tsukimoto M, Harada H, Ikari A, Takagi K (2005) Involvement of chloride in apoptotic cell death induced by activation of ATP-sensitive P2X7 purinoceptor. J Biol Chem 280: 2653-2658
81. Woods A, Ciruela F, Fuxe K, Agnati LF, Lluis C, Franco R, Ferre S (2005) The role of electrostatic interactions in receptor-receptor heteromerization. J Mol Neurosci 26: 125-132
82. Zoli M, Agnati LF, Hedlund PB, Li XM, Ferre S, Fuxe K (1993) Receptor-receptor interactions as an integrative mechanism in nerve cells. Mol Neurobiol 7: 293-334